Docoh
Loading...

ENZ Enzo Biochem

Filed: 25 Nov 20, 5:00pm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): November 25, 2020

 

Enzo Biochem, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

New York

(State or Other Jurisdiction of Incorporation)

 

001-0997413-2866202
(Commission File Number)(IRS Employer Identification No.)
  
527 Madison Avenue 
New York, New York10022
(Address of Principal Executive Offices)(Zip Code)

 

(212) 583-0100

(Registrant’s Telephone Number, Including Area Code)

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of Each ClassTrading SymbolName of Each Exchange on Which Registered
Common Stock, $.01 par valueENZThe New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-1 of this chapter). 

Emerging growth company     ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

Item 5.02       Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

On November 25, 2020, Ian B. Walters, M.D. was appointed by the Board of Directors (the “Board”) of Enzo Biochem, Inc. (the “Company”) as a Class III director, effective immediately. The Board has determined that Dr. Walters meets the independence standards adopted by the Board in compliance with the New York Stock Exchange corporate governance listing standards and Item 407(a) of Regulation S-K.

 

The Company issued a press release announcing the appointment to the Board of Dr. Walters as a Class III director, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01       Financial Statements, Pro Forma Financial Information and Exhibits

 

(d)Exhibits

 

Exhibit No.Description
  
99.1Press Release issued by Enzo Biochem, Inc. on November 25, 2020
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 ENZO BIOCHEM, INC.
    
Date: November 25, 2020By:/s/ David Bench 
  David Bench 
  Chief Financial Officer 
 
0000316253 2020-11-25 2020-11-25